Stakeholder Political Alliance For Radioligand Cancer Therapies

Improving tailored cancer care and patients' quality of life

SPARC-Europe is a European policy initiative aiming to build an adequate policy environment for radioligand therapies by ensuring that policy initiatives of the European Union reflect the specific characteristics of these therapies. 

Our mission

1

Provide expert knowledge to support policymakers in strengthening European cancer care

2

Guide policymakers on how to overcome the current barriers of accessibility of radioligand therapies

3

Provide the patient voice to advise experts and policymakers on how to improve patient treatment outcomes

4

Engage with relevant decision and policymakers to address the existing geographical variations in access to radioligand therapies

Steering Committee Members

Mark McDonnell

Mark McDonnell

International Neuroendocrine Cancer Alliance
Andre Deschamps

Andre Deschamps

Europa Uomo
Prof. Ken Herrmann

Prof. Ken Herrmann

University Hospital Essen
Prof. Dermot O‘Toole

Prof. Dermot O‘Toole

Trinity College Dublin
Prof. Martyn Caplin

Prof. Martyn Caplin

Royal Free Hospital and University College London
Dr. Nicola Fazio

Dr. Nicola Fazio

European Institute of Oncology, Milano
Dr. Luka Ležaić

Dr. Luka Ležaić

University Medical Centre Ljubljana
Prof. Ignasi Carrió

Prof. Ignasi Carrió

Autonomous University of Barcelona, Research Institute, Hospital Sant Pau

Latest publications

Harnessing the Opportunities of Radioligand Therapies: Infrastructure and Education - A SPARC-Europe Event at the European Parliament

SPARC-Europe’s first in-person event at the European Parliament, hosted by MEP Geuking. The vent will focus on exploring how to build a sustainable health infrastructure for radioligand therapies and leverage EU funds for innovation and impact. As well as, discussing how to empower professionals and…

Preventable yet not prevented: spotlight on prostate cancer

SPARC-Europe fully welcomes the Commission’s proposal for a step-by-step approach to introducing new organised cancer testing in the European Union, as early and accurate diagnosis by strengthening evidence-based screening programmes are core elements of cancer care.

Improving European policies to unlock radioligand therapies’ potential: what is the state of play?

The event will serve as an opportunity to take stock of progress made thus far in the field of cancer care at the EU level. The implementation of Europe’s Beating Cancer Plan in synergy with other EU healthcare initiatives such as the SAMIRA Action Plan, EU4Health programme or Horizon Europe, prove…